Johnson & Johnson’s HIV vaccine trial delivers disappointing results
Last week, Johnson & Johnson announced that the HIV vaccine trial known as Imbokodo (HVTN705/HPX2008) failed to significantly reduce the risk of acquiring HIV in over 2,600 women across five sub-Saharan African countries. The initial data showed a 25% efficacy estimate, ...